Table A1. Detail of studies used to calculate vaccine efficacy.1.
| Name of the study | Source | |
|---|---|---|
| Kaiser Permanente Vaccine Study | 23 , 24 | PCV7 vs. meningococcal vaccine (control) USA (Northern California) Aim: To evaluate protective efficacy of PCV7 against invasive pneumococcal disease caused by vaccine serotypes, clinical episodes of otitis media and episodes of pneumonia. |
| Finnish Otitis Media Vaccine Trial | 25 | PCV7 vs. hepatitis vaccine (control) Finland Aim: To evaluate protective efficacy of PCV7 against episodes of acute otitis media. |
| Pneumococcal Otitis Efficacy Trial (POET) | 16 | PCV11 vs. hepatitis vaccine (control) Czech Republic and Slovakia. Aim: to evaluate protective efficacy against acute otitis media caused by pneumococci and nontypable H. influenza. |
| Finnish Invasive Pneumococcal disease (FinIP) | 11 | PCV10 vs. hepatitis vaccine (control) Finland Aim: To evaluate protection against several disease endpoints associated with S. pneumoniae and non-typeable H. influenzae. |
| Clinical Otitis Media and Pneumonia Study (COMPAS) | 13 | PCV10 vs. hepatitis vaccine (control) Latin America Aim: to evaluate protective efficacy against acute otitis media. |
(1) PCV: Pneumococcal Conjugate Vaccine